L-ergothioneine and Metformin Alleviates Liver Injury in Experimental Type-2 Diabetic Rats via Reduction of Oxidative Stress, Inflammation, and Hypertriglyceridemia
Abstract
Abstract Diabetic-induced liver toxicity is a serious complication that cause significant metabolic dysfunction. L-ergothioneine (L-egt) is a bioactive nutraceutical obtained from mushrooms and certain food products, with reported cytoprotective, antioxidant and anti-inflammatory properties and potential to improve efficacy of existing therapy. Thus, this study evaluates the effects of L-egt, and/or metformin, on diabetes-induced liver injury. Diabetes was induced in male Sprague-Dawley rats using 10% fructose for two weeks, followed by a single low dose streptozotocin (STZ, 40 mg/kg i.p) injection. After induction of diabetes, animals were treated either with de-ionized water (DW), L-egt (35 mg/kg bwt), metformin (500 mg/kg bwt), or a combination of L-egt and metformin orally for seven weeks. Body weight and glucose were monitored during the experiment. At the completion of experiment, blood samples were collected, and liver tissue was excised for biochemical analysis, enzyme-link immunosorbent assay (ELISA) of various liver function biomarkers, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis of genes associated with inflammation, oxidative stress, and lipid metabolism, as well as histopathological evaluation. Diabetic animals showed liver hypertrophy, increased liver injury, hepatic triglycerides, oxidative stress, and hepatic inflammation. However, L-egt, and/or metformin, improved glycemic control, reduced liver injury, triglycerides,…
How strong is the evidence?
Evidence Hub reads this as a preprint, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.